Literature DB >> 27725639

Oligometastatic prostate cancer: definitions, clinical outcomes, and treatment considerations.

Jeffrey J Tosoian1, Michael A Gorin1, Ashley E Ross1, Kenneth J Pienta1, Phuoc T Tran2, Edward M Schaeffer3.   

Abstract

The oligometastatic state has been proposed as an intermediate stage of cancer spread between localized disease and widespread metastases. With improvements in diagnostic modalities such as functional imaging, oligometastatic prostate cancer is being diagnosed with greater frequency than ever before. Furthermore, the paradigm for treatment of advanced prostate cancers is shifting toward a more aggressive approach. Many questions surround the understanding of the process and consequences of oligometastasis, meaning that the contemporary literature offers a wide variety of definitions of oligometastatic prostate cancer. Until genomic data exist to provide a biological component to the definition of oligometastatic disease, a clinical diagnosis made on the basis of up to five extrapelvic lesions is reasonable for use. Retrospective studies suggest that interventions such as radical prostatectomy and local or metastasis-directed radiotherapy can be performed in the metastatic setting with minimal risk of toxic effects. These therapies seem to decrease the need for subsequent palliative interventions, but insufficient data are available to draw reliable conclusions regarding their effect on survival. Thus, a protocol for clinicians to manage the patient presenting with oligometastatic prostate cancer would be a useful clinical tool.

Entities:  

Mesh:

Year:  2016        PMID: 27725639      PMCID: PMC5808411          DOI: 10.1038/nrurol.2016.175

Source DB:  PubMed          Journal:  Nat Rev Urol        ISSN: 1759-4812            Impact factor:   14.432


  86 in total

1.  Gene-expression profile changes correlated with tumor progression and lymph node metastasis in esophageal cancer.

Authors:  Eiji Tamoto; Mitsuhiro Tada; Katsuhiko Murakawa; Minoru Takada; Gaku Shindo; Ken-ichi Teramoto; Akihiro Matsunaga; Kazuteru Komuro; Motoshi Kanai; Akiko Kawakami; Yoshie Fujiwara; Nozomi Kobayashi; Katsutoshi Shirata; Norihiro Nishimura; Shun-ichi Okushiba; Satoshi Kondo; Jun-ichi Hamada; Takashi Yoshiki; Tetsuya Moriuchi; Hiroyuki Katoh
Journal:  Clin Cancer Res       Date:  2004-06-01       Impact factor: 12.531

Review 2.  Solitary metastases: illusion versus reality.

Authors:  Philip Rubin; Ralph Brasacchio; Alan Katz
Journal:  Semin Radiat Oncol       Date:  2006-04       Impact factor: 5.934

Review 3.  Current use of PSMA-PET in prostate cancer management.

Authors:  Tobias Maurer; Matthias Eiber; Markus Schwaiger; Jürgen E Gschwend
Journal:  Nat Rev Urol       Date:  2016-02-23       Impact factor: 14.432

Review 4.  Treatment of the Primary Tumor in Metastatic Prostate Cancer: Current Concepts and Future Perspectives.

Authors:  Christopher E Bayne; Stephen B Williams; Matthew R Cooperberg; Martin E Gleave; Markus Graefen; Francesco Montorsi; Giacomo Novara; Marc C Smaldone; Prasanna Sooriakumaran; Peter N Wiklund; Brian F Chapin
Journal:  Eur Urol       Date:  2015-05-21       Impact factor: 20.096

5.  Long-term results of lung metastasectomy: prognostic analyses based on 5206 cases.

Authors:  U Pastorino; M Buyse; G Friedel; R J Ginsberg; P Girard; P Goldstraw; M Johnston; P McCormack; H Pass; J B Putnam
Journal:  J Thorac Cardiovasc Surg       Date:  1997-01       Impact factor: 5.209

Review 6.  Molecular imaging of urogenital diseases.

Authors:  Steve Y Cho; Zsolt Szabo
Journal:  Semin Nucl Med       Date:  2014-03       Impact factor: 4.446

7.  Radical radiation for localized prostate cancer: local persistence of disease results in a late wave of metastases.

Authors:  John J Coen; Anthony L Zietman; Harjot Thakral; William U Shipley
Journal:  J Clin Oncol       Date:  2002-08-01       Impact factor: 44.544

8.  Primary treatment of the prostate improves local palliation in men who ultimately develop castrate-resistant prostate cancer.

Authors:  Andy C M Won; Howard Gurney; Gavin Marx; Paul De Souza; Manish I Patel
Journal:  BJU Int       Date:  2013-08       Impact factor: 5.588

Review 9.  Metastasis-directed therapy of regional and distant recurrences after curative treatment of prostate cancer: a systematic review of the literature.

Authors:  Piet Ost; Alberto Bossi; Karel Decaestecker; Gert De Meerleer; Gianluca Giannarini; R Jeffrey Karnes; Mack Roach; Alberto Briganti
Journal:  Eur Urol       Date:  2014-09-17       Impact factor: 20.096

10.  Stereotactic body radiation therapy in the treatment of oligometastatic prostate cancer.

Authors:  Kamran A Ahmed; Brandon M Barney; Brian J Davis; Sean S Park; Eugene D Kwon; Kenneth R Olivier
Journal:  Front Oncol       Date:  2013-01-22       Impact factor: 6.244

View more
  71 in total

Review 1.  The Evolving Systemic Treatment Landscape for Patients with Advanced Prostate Cancer.

Authors:  Martina Pagliuca; Carlo Buonerba; Karim Fizazi; Giuseppe Di Lorenzo
Journal:  Drugs       Date:  2019-03       Impact factor: 9.546

Review 2.  PSMA PET applications in the prostate cancer journey: from diagnosis to theranostics.

Authors:  R S Eapen; T C Nzenza; D G Murphy; M S Hofman; M Cooperberg; N Lawrentschuk
Journal:  World J Urol       Date:  2018-10-29       Impact factor: 4.226

3.  Follow-up of Lesions with Equivocal Radiotracer Uptake on PSMA-Targeted PET in Patients with Prostate Cancer: Predictive Values of the PSMA-RADS-3A and PSMA-RADS-3B Categories.

Authors:  Yafu Yin; Rudolf A Werner; Takahiro Higuchi; Constantin Lapa; Kenneth J Pienta; Martin G Pomper; Michael A Gorin; Steven P Rowe
Journal:  J Nucl Med       Date:  2018-09-06       Impact factor: 10.057

4.  Stereotactic ablative radiation therapy for oligometastatic prostate cancer delays time-to-next systemic treatment.

Authors:  C Leigh Moyer; Ryan Phillips; Matthew P Deek; Noura Radwan; Ashley E Ross; Emmanuel S Antonarakis; Diane Reyes; Jean Wright; Stephanie A Terezakis; Daniel Y Song; Curtiland DeVille; Patrick C Walsh; Theodore L DeWeese; Michael Carducci; Edward M Schaeffer; Kenneth J Pienta; Mario Eisenberger; Phuoc T Tran
Journal:  World J Urol       Date:  2018-09-06       Impact factor: 4.226

5.  Case: Testicular oligometastasis from prostate cancer - Report of rare isolated recurrence after radiotherapy and intermittent androgen-deprivation therapy.

Authors:  Chan-Kyung J Cho; Samantha Sigurdson; Christopher M Davidson; Michael Leveridge; Aamer Mahmud
Journal:  Can Urol Assoc J       Date:  2017-12-01       Impact factor: 1.862

6.  Proposal for a Structured Reporting System for Prostate-Specific Membrane Antigen-Targeted PET Imaging: PSMA-RADS Version 1.0.

Authors:  Steven P Rowe; Kenneth J Pienta; Martin G Pomper; Michael A Gorin
Journal:  J Nucl Med       Date:  2017-09-08       Impact factor: 10.057

7.  Developments in oligometastatic hormone-sensitive prostate cancer.

Authors:  Phuoc T Tran; Piet Ost
Journal:  World J Urol       Date:  2019-12       Impact factor: 4.226

Review 8.  Expanding the role of small-molecule PSMA ligands beyond PET staging of prostate cancer.

Authors:  Shankar Siva; Cristian Udovicich; Ben Tran; Homi Zargar; Declan G Murphy; Michael S Hofman
Journal:  Nat Rev Urol       Date:  2020-01-14       Impact factor: 14.432

9.  Pattern of metastatic deposit in recurrent prostate cancer: a whole-body MRI-based assessment of lesion distribution and effect of primary treatment.

Authors:  Vassiliki Pasoglou; Nicolas Michoux; Julien Van Damme; Sandy Van Nieuwenhove; Marin Halut; Perrine Triqueneaux; Bertrand Tombal; Frédéric E Lecouvet
Journal:  World J Urol       Date:  2019-03-02       Impact factor: 4.226

10.  Post prostatectomy outcomes of patients with high-risk prostate cancer treated with neoadjuvant androgen blockade.

Authors:  Rana R McKay; Bruce Montgomery; Wanling Xie; Zhenwei Zhang; Glenn J Bubley; David W Lin; Mark A Preston; Quoc-Dien Trinh; Peter Chang; Andrew A Wagner; Elahe A Mostaghel; Philip W Kantoff; Peter S Nelson; Adam S Kibel; Mary-Ellen Taplin
Journal:  Prostate Cancer Prostatic Dis       Date:  2017-12-20       Impact factor: 5.554

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.